A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Clinical trial NCT07497386 · RECRUITING

Trial details

NCT number: NCT07497386
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Unresectable Locally Recurrent Breast Cancer Unresectable Locally Metastatic Breast Cancer

Start date: 2026-04-28
Primary completion: 2028-06-01
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.